Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.830
-0.020 (-1.08%)
Apr 10, 2026, 4:00 PM EDT - Market closed
Daré Bioscience Employees
As of December 31, 2025, Daré Bioscience had 24 total employees, including 21 full-time and 3 part-time employees. The number of employees increased by 1 or 4.35% compared to the previous year.
Employees
24
Change (1Y)
1
Growth (1Y)
4.35%
Revenue / Employee
$42,925
Profits / Employee
-$558,303
Market Cap
26.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | 1 | 4.35% | 21 | 3 |
| Dec 31, 2024 | 23 | -3 | -11.54% | 21 | 2 |
| Dec 31, 2023 | 26 | -4 | -13.33% | 23 | 3 |
| Dec 31, 2022 | 30 | 2 | 7.14% | 25 | 5 |
| Dec 31, 2021 | 28 | 5 | 21.74% | 20 | 8 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Senti Biosciences | 34 |
| Kyntra Bio | 34 |
| Boundless Bio | 28 |
| Outlook Therapeutics | 17 |
| NeuroSense Therapeutics | 17 |
| Serina Therapeutics | 13 |
| Apollomics | 13 |
DARE News
- 17 days ago - Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 21 days ago - On National Viagra Day, Women Finally Claim Their Turn: - GlobeNewsWire
- 4 weeks ago - Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - GlobeNewsWire
- 4 weeks ago - Daré Bioscience Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 6 weeks ago - Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 4 months ago - DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - GlobeNewsWire
- 5 months ago - Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - GlobeNewsWire